Lead Heart Trial Beats Faster for Mesoblast; Interim Analysis Encouraging
We are raising our fair value estimate to AUD 2.80 per share from AUD 2.30 for no-moat Mesoblast Ltd (MSB AU), following the encouraging interim...
238 Views
A Storm Will Follow the Lull
Newsflow around the US and state governments' antitrust investigations of the generic drug industry has been quiet since mid-December. Some lull is...
846 Views
Indictments Starting to Appear
The US Department of Justice (DOJ) filed charges (attached) against two former senior executives of Heritage Pharmaceuticals, a subsidiary of Pune,...
426 Views
'Cures Act', Halol Plant FDA Inspection and a Russian Acquisition.
We continue to be bullish on Sun Pharmaceutical Indus (SUNP IN) after the recent news of progress in passing the '21st century Cures Act' in the...
454 Views
Laurus Labs: Final Thoughts
The company has announced a price range of Rs 426 - 428 per share for its listing with bidding set to open on 6 December and closing on 8 December...
354 Views